Lineage Therap Expands ATM Equity Offering Capacity

Lineage Cell Therapeutics, Inc. has expanded its at-the-market equity offering capacity by filing a new prospectus supplement with the U.S. SEC, allowing it to sell an additional $60 million in common shares. This follows approximately $22.6 million previously sold, enhancing its financial flexibility for operations and growth. The current analyst rating for LCTX stock is a Hold with a $2.00 price target, reflecting concerns over financial performance despite an extended funding runway and operational milestones. Lineage focuses on developing cell-based therapies in the U.S. life sciences sector.